Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies

Fig. 1

Overview of study design and treatment schedule in Studies 1, 2, and 3. Azacitidine was given at 75 mg/m2 to all patients in Studies 1 and 2, and approximately half of patients in Study 3. All planned cycles were 28 days. Aza, azacitidine; D, day; EOT, end of treatment; FU, follow-up

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us